Nuvectis Pharma, Inc. — Form 8-K

Nuvectis Pharma, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026, authorizing the sale of common stock with aggregate offering price up to the Maximum Program Amount (limited by registration statement size, authorized unissued shares, Form S-3 rules, or prospectus filing). The company may issue shares at variable prices set via Issuance Notices; Jefferies receives a 3% selling commission. No specific dollar cap or share count is stated—the maximum is determined by the lesser of four regulatory/corporate constraints. The agreement permits sales over an indefinite Agency Period until terminated or the maximum is reached.